TrialCancer research and treatment2026

Nivolumab Plus Chemotherapy versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4).

Yoon-Koo Kang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.